UroGen Pharma (URGN) 주식 개요
생명공학 회사인 UroGen Pharma는 요로상피암 및 특수 암에 대한 솔루션 개발 및 상용화에 종사하고 있습니다. 자세히 보기
URGN Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
UroGen Pharma Ltd. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$38.02 |
| 52주 최고가 | US$39.59 |
| 52주 최저가 | US$13.26 |
| 베타 | 1.57 |
| 1개월 변동 | 41.60% |
| 3개월 변동 | 104.30% |
| 1년 변동 | 179.97% |
| 3년 변동 | 223.85% |
| 5년 변동 | 154.31% |
| IPO 이후 변동 | 171.96% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 18
URGN: Patent Overhang And Execution Risks Will Likely Cap Stock Price Upside
Analysts have trimmed their average price target for UroGen Pharma to about $20.55, a slight adjustment they link to updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research around UroGen Pharma highlights a mix of optimism on the product story and tighter scrutiny on what that implies for valuation, especially relative to updated assumptions on revenue, margins and future P/E multiples.
내러티브 업데이트 • Jun 04
URGN: Future Bladder Cancer Trial Milestones May Reframe Long Term Upside Potential
Analysts have reset the 12 month price target for UroGen Pharma to $45.00, reflecting updated assumptions around revenue growth, profit margins, and a slightly higher discount rate, while citing supportive recent research coverage and target increases from multiple firms. Analyst Commentary Recent research coverage on UroGen Pharma has leaned positive, with several bullish analysts updating their views and models following new information on the company and its pipeline.내러티브 업데이트 • May 21
URGN: Future Regulatory And Funding Setbacks Will Likely Restrain Upside Potential
Narrative Update on UroGen Pharma The updated analyst price target for UroGen Pharma has shifted from about $19.68 to roughly $20.86 as analysts incorporate recent initiations and target increases, including the $5 and $6 target hikes and renewed Buy views, into their valuation work. Analyst Commentary Recent research on UroGen Pharma has leaned constructive, with several firms initiating or reaffirming Buy views and lifting their price targets.Recent updates
내러티브 업데이트 • Jun 18
URGN: Patent Overhang And Execution Risks Will Likely Cap Stock Price Upside
Analysts have trimmed their average price target for UroGen Pharma to about $20.55, a slight adjustment they link to updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research around UroGen Pharma highlights a mix of optimism on the product story and tighter scrutiny on what that implies for valuation, especially relative to updated assumptions on revenue, margins and future P/E multiples.내러티브 업데이트 • Jun 04
URGN: Future Bladder Cancer Trial Milestones May Reframe Long Term Upside Potential
Analysts have reset the 12 month price target for UroGen Pharma to $45.00, reflecting updated assumptions around revenue growth, profit margins, and a slightly higher discount rate, while citing supportive recent research coverage and target increases from multiple firms. Analyst Commentary Recent research coverage on UroGen Pharma has leaned positive, with several bullish analysts updating their views and models following new information on the company and its pipeline.내러티브 업데이트 • May 21
URGN: Future Regulatory And Funding Setbacks Will Likely Restrain Upside Potential
Narrative Update on UroGen Pharma The updated analyst price target for UroGen Pharma has shifted from about $19.68 to roughly $20.86 as analysts incorporate recent initiations and target increases, including the $5 and $6 target hikes and renewed Buy views, into their valuation work. Analyst Commentary Recent research on UroGen Pharma has leaned constructive, with several firms initiating or reaffirming Buy views and lifting their price targets.Seeking Alpha • May 07
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
Summary UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue. Risks include execution on Zusduri adoption, debt burden, and long-term generic threats, but current sales momentum and operating leverage support the bullish thesis. Read the full article on Seeking Alpha내러티브 업데이트 • May 03
URGN: Future Regulatory And Cost Setbacks Will Likely Restrain Upside Potential
Analysts have raised their price target on UroGen Pharma from $16.57 to $19.68 as updated assumptions for revenue growth, profit margins and a lower future P/E multiple align with a recently initiated bullish view on the stock. Analyst Commentary Recent research commentary on UroGen Pharma reflects a bullish initiation that aligns with the higher price target.
내러티브 업데이트 • Apr 18
URGN: Future Profit Margins Will Improve Through LG UTUC Trial Momentum
Analysts have nudged their price target for UroGen Pharma higher to $36.11 from $35.63, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E following recent bullish Street research coverage. Analyst Commentary Recent Street research on UroGen Pharma has leaned constructive, which feeds into the modest uptick in the blended price target to $36.11.내러티브 업데이트 • Apr 03
URGN: Future Profit Margins Will Improve Through New J Code Reimbursement
Analysts have modestly fine-tuned their price target framework for UroGen Pharma, keeping fair value around $35.63. Small adjustments to the discount rate, revenue growth, profit margin, and forward P/E reflect updated assumptions rather than a major change in outlook.내러티브 업데이트 • Mar 20
URGN: Future Profit Margins Will Benefit From New J Code And Loan Refinancing
Analysts kept their fair value estimate for UroGen Pharma steady at $35.63 while making only minimal adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E. These changes reflect updated views on operating costs and financing conditions, similar to those that recently led to modest target reductions in other healthcare names.내러티브 업데이트 • Mar 05
URGN: Future Profit Margins Will Benefit From New J Code Reimbursement
Analysts now place UroGen Pharma's fair value at about $35.63, compared with the prior $35.25. This reflects updated assumptions around a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a higher future P/E estimate.분석 기사 • Dec 05
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders have had their patience rewarded with a 26% share price jump in the...내러티브 업데이트 • Nov 26
URGN: Future Profit Margins Will Benefit From Recent Regulatory Milestones
Analysts have raised their price target for UroGen Pharma from $33.75 to $35.25. They cite expectations of stronger revenue growth and improved profit margins as key drivers for the increase.분석 기사 • Oct 06
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues
It's not a stretch to say that UroGen Pharma Ltd.'s ( NASDAQ:URGN ) price-to-sales (or "P/S") ratio of 8.5x right now...내러티브 업데이트 • Sep 09
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Driven by an improved net profit margin and a modest reduction in future P/E, analysts have raised UroGen Pharma’s consensus price target from $32.00 to $33.75. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only approved therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.내러티브 업데이트 • Aug 15
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
As there is no change in the key metrics—consensus price target ($31.43), discount rate (6.85%), and future P/E (15.67x)—analyst valuation for UroGen Pharma remains steady, reflecting an unchanged fair value. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.분석 기사 • Aug 10
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
NasdaqGM:URGN 1 Year Share Price vs Fair Value Explore UroGen Pharma's Fair Values from the Community and select yours...분석 기사 • Jul 07
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...분석 기사 • May 17
Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop
The UroGen Pharma Ltd. ( NASDAQ:URGN ) share price has fared very poorly over the last month, falling by a substantial...분석 기사 • May 15
Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
It's shaping up to be a tough period for UroGen Pharma Ltd. ( NASDAQ:URGN ), which a week ago released some...새로운 내러티브 • May 07
UGN-102 Approval Will Broaden Bladder Cancer Treatment Options
Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.분석 기사 • Feb 12
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 4.8x UroGen Pharma Ltd. ( NASDAQ:URGN ) is definitely a...Seeking Alpha • Jan 31
UroGen: Upcoming PDUFA, Some Concerns Remain
Summary UroGen's Jelmyto, a gel-based mitomycin product for LG-UTUC, achieved $25.2mn in Q3 2024, marking a 20% YoY increase. Lead candidate UGN-102 shows promise in treating low-grade intermediate risk NMIBC, with significant clinical trial success and a PDUFA date set for June 13, 2025. Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap suggests caution; a pilot investment is recommended with awareness of associated risks. Read the full article on Seeking Alpha분석 기사 • Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 28
UroGen Pharma: There Is Some Potential Here
Summary UroGen Pharma Ltd. focuses on urothelial and specialty cancers, with Jelmyto approved for LG-UTUC and promising pipeline candidates like UGN-102 for bladder cancer. UGN-102 should garner FDA approval in the first half of 2025 and has a much bigger potential market than Jelmyto. UroGen is also advancing some next-generation candidates within its pipeline and has adequate near-term funding in place. An analysis around UroGen Pharma follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 17
UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Summary ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102. Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potential for priority review. UroGen Pharma's blockbuster drug potential, liquidity, and modest market cap make it a strong buy. Read the full article on Seeking Alpha분석 기사 • Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Apr 09
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
UroGen Pharma Ltd. ( NASDAQ:URGN ) shares have had a horrible month, losing 27% after a relatively good period...Seeking Alpha • Mar 18
UroGen: All Eyes On UGN-102
Summary JELMYTO revenues are growing but not by enough to support UroGen's operations. Guided financials show ongoing losses with adequate liquidity for its near-term UGN-102 development. If all goes as hoped, UroGen will launch UGN-102 in Q1 2025. Read the full article on Seeking Alpha분석 기사 • Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
It's been a sad week for UroGen Pharma Ltd. ( NASDAQ:URGN ), who've watched their investment drop 20% to US$14.46 in...분석 기사 • Jan 18
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
UroGen Pharma Ltd.'s ( NASDAQ:URGN ) price-to-sales (or "P/S") ratio of 6.2x might make it look like a strong buy right...주주 수익률
| URGN | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | 10.1% | 4.1% | 1.6% |
| 1Y | 180.0% | 41.1% | 18.6% |
수익률 대 산업: URGN은 지난 1년 동안 41.1%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: URGN은 지난 1년 동안 18.6%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| URGN volatility | |
|---|---|
| URGN Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: URGN는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: URGN의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2004 | 298 | Liz Barrett | www.urogen.com |
생명공학 회사인 UroGen Pharma는 요로암 및 특수 암에 대한 솔루션 개발 및 상용화에 종사하고 있습니다. 이 회사는 새로운 독점 고분자 생체 적합성 역열 겔화 하이드로겔 기술인 RTGel, 방광 종양의 경요도 절제술 후 저등급 NMIBC 치료를 위한 보조 화학 요법으로 오프 라벨로 사용되는 일반 의약품인 미토마이신, 비근육 침습성 방광암(NMIBC) 치료를 위한 미토마이신 서방형 제제인 주스두리, 신우신염 용액용 젤마이토를 공급합니다. 회사의 주요 제품 후보로는 정맥 내 용액으로 임상 3상 단계에 있는 UGN-103과 저등급 상부 요로상피암 및 저등급 중간 위험 NMIBC를 포함한 여러 형태의 비근육 침습성 요로상피암 치료를 위해 설계된 신세포 용액으로 임상 3상 단계에 있는 UGN-104가 있습니다.
UroGen Pharma Ltd. 기초 지표 요약
| URGN 기초 통계 | |
|---|---|
| 시가총액 | US$1.85b |
| 순이익 (TTM) | -US$133.22m |
| 매출 (TTM) | US$140.49m |
13.2x
주가매출비율(P/S)-13.9x
주가수익비율(P/E)URGN는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| URGN 손익계산서 (TTM) | |
|---|---|
| 매출 | US$140.49m |
| 매출원가 | US$14.26m |
| 총이익 | US$126.24m |
| 기타 비용 | US$259.46m |
| 순이익 | -US$133.22m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -2.73 |
| 총이익률 | 89.85% |
| 순이익률 | -94.83% |
| 부채/자본 비율 | -152.5% |
URGN의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/05 02:11 |
| 종가 | 2026/07/02 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
UroGen Pharma Ltd.는 22명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Anita Dushyanth | Berenberg |
| Jason Kolbert | D. Boral Capital LLC. |
| Paul Choi | Goldman Sachs |